fish logo

Littler falls victim to Humphries in Players Championship final

JACKSONVILLE, Fla., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Landstar System, Inc. (NASDAQ-LSTR), a technology-enabled, asset-light provider of integrated transportation management solutions delivering safe, specialized transportation logistics services, announced that on December 9, 2024, its Board of Directors has declared a special one-time cash dividend in the amount of $2.00 per share, payable on January 21, 2025, to stockholders of record as of the close of business on January 7, 2025. “Landstar’s strong balance sheet and free cash flow generation enable us to continue to return value to our stockholders,” said Landstar President and Chief Executive Officer Frank Lonegro. The Company purchased a total of 452,019 shares of its common stock at an aggregate cost of approximately $82.1 million during the first 11 months of its 2024 fiscal year. The Company also returned $120.5 million to stockholders in the form of cash dividends paid on shares of its common stock during the 2024 fiscal year. As previously reported, as of September 28, 2024, the Company had $531 million in cash and short-term investments. The Company intends to continue to use its available free cash flow to opportunistically purchase its stock under its stock purchase program. About Landstar: Landstar System, Inc., is a technology-enabled, asset-light provider of integrated transportation management solutions delivering safe, specialized transportation services to a broad range of customers utilizing a network of agents, third-party capacity providers and employees. Landstar transportation services companies are certified to ISO 9001:2015 quality management system standards and RC14001:2015 environmental, health, safety and security management system standards. Landstar System, Inc. is headquartered in Jacksonville, Florida. Its common stock trades on The NASDAQ Stock Market® under the symbol LSTR. Forward Looking Statements Disclaimer: The following is a “safe harbor” statement under the Private Securities Litigation Reform Act of 1995. Statements contained in this press release that are not based on historical facts are “forward-looking statements.” This press release contains forward-looking statements, such as statements which relate to Landstar’s business objectives, plans, strategies and expectations. Terms such as “anticipates,” “believes,” “estimates,” “intention,” “expects,” “plans,” “predicts,” “may,” “should,” “could,” “will,” the negative thereof and similar expressions are intended to identify forward-looking statements. Such statements are by nature subject to uncertainties and risks, including but not limited to: an increase in the frequency or severity of accidents or other claims; unfavorable development of existing accident claims; dependence on third party insurance companies; dependence on independent commission sales agents; dependence on third party capacity providers; the impact of the Russian conflict with Ukraine on the operations of certain independent commission sales agents, including the Company’s largest such agent by revenue in the 2023 fiscal year; decreased demand for transportation services; U.S. trade relationships; substantial industry competition; disruptions or failures in the Company’s computer systems; cyber and other information security incidents; dependence on key vendors; potential changes in taxes; status of independent contractors; regulatory and legislative changes; regulations focused on diesel emissions and other air quality matters; regulations requiring the purchase and use of zero-emission vehicles; intellectual property; and other operational, financial or legal risks or uncertainties detailed in Landstar’s Form 10-K for the 2023 fiscal year, described in Item 1A Risk Factors, and in other SEC filings from time to time. These risks and uncertainties could cause actual results or events to differ materially from historical results or those anticipated. Investors should not place undue reliance on such forward-looking statements, and the Company undertakes no obligation to publicly update or revise any forward-looking statements.Tagovailoa carves up Pats with 4 TDs, Dolphins win 3rd straight game with 34-15 rout of New England

TROY, N.Y. — The Rensselaer Polytechnic Institute Engineers (5-5-1) men’s hockey team faced a tall task as they hosted the No. 5 University of Maine Black Bears (9-2-2) at Houston Field House on Saturday afternoon in Troy. In the first of a two-game set, the Black Bears slowly built up a lead and busted it [...]The 26-year-old man charged in last week’s killing of UnitedHealthcare’s CEO appeared in a Pennsylvania courtroom Tuesday, where he was denied bail and his lawyer said he'd fight extradition to New York City, where the attack happened. Luigi Nicholas Mangione was arrested Monday in the Dec. 4 attack on Brian Thompson after police say a worker at a McDonald’s in Altoona, Pennsylvania, alerted them to a customer who resembled the suspected gunman. When arrested, Mangione had on him a gun that investigators believe was used in the attack and writings expressing anger at corporate America, police said. As Mangione was led into the Hollidaysburg courthouse Tuesday, he struggled with officers and shouted something that was partly unintelligible but referred to an “insult to the intelligence of the American people.” He left hours later without saying anything and was driven away. Mangione is being held on Pennsylvania charges of possession of an unlicensed firearm, forgery and providing false identification to police. Manhattan prosecutors have charged him with five counts, including murder, criminal possession of a weapon and criminal possession of a forged instrument. Wearing an orange jumpsuit, Mangione mostly stared straight ahead during the hearing, occasionally consulting papers, rocking in his chair, or looking back at the gallery. At one point, he began to speak to respond to the court discussion but was quieted by his lawyer. Judge David Consiglio denied bail to Mangione, whose attorney, Thomas Dickey, told the court that his client did not agree to extradition and wants a hearing on the matter. Blair County (Pennsylvania) District Attorney Peter Weeks said that although Mangione will create “extra hoops” for law enforcement to jump through by fighting extradition, it won’t be a substantial barrier to sending him to New York. In addition to a three-page, handwritten document that suggests he harbored “ill will toward corporate America,” NYPD Chief of Detectives Joseph Kenny said Monday that Mangione also had a ghost gun, a type of weapon that can be assembled at home and is difficult to trace. Officers questioned Mangione, who was acting suspiciously and carrying multiple fraudulent IDs, as well as a U.S. passport, New York Police Commissioner Jessica Tisch said. Officers also found a sound suppressor, or silencer, “consistent with the weapon used in the murder,” she said. He had clothing and a mask similar to those worn by the shooter and a fraudulent New Jersey ID matching one the suspect used to check into a New York City hostel before the shooting, the commissioner said. Mangione, who comes from a prominent Maryland family, was valedictorian of his elite Baltimore prep school and had degrees from one of the nation’s top private universities. He earned undergraduate and graduate degrees in computer science in 2020 from the University of Pennsylvania. Mangione's grandfather Nick Mangione, who died in 2008, was a successful real estate developer. One of his best-known projects was Turf Valley Resort, a sprawling luxury retreat and conference center outside Baltimore that he purchased in 1978. One of Luigi Mangione’s cousins is Republican Maryland state legislator Nino Mangione, a spokesman for the lawmaker’s office confirmed. From January to June 2022, Mangione lived at Surfbreak, a “co-living” space at the edge of touristy Waikiki in Honolulu. Josiah Ryan, a spokesperson for owner and founder R.J. Martin, said that Martin had learned that Mangione had severe back pain from childhood that interfered with many aspects of his life. Friends in Hawaii widely considered Mangione a “great guy,” and pictures on his social media accounts show a fit and smiling young man on beaches and at parties. Mangione likely was motivated by his anger at what he called “parasitic” health insurance companies and a disdain for corporate greed, according to a law enforcement bulletin obtained by The Associated Press. He wrote that the U.S. has the most expensive healthcare system in the world and that the profits of major corporations continue to rise while “our life expectancy” does not, according to the bulletin, based on a review of the suspect’s handwritten notes and social media posts. Police said the person who killed Thompson left a hostel on Manhattan's Upper West Side at 5:41 a.m. last Wednesday. Eleven minutes later, he was seen on surveillance video walking back and forth in front of the New York Hilton Midtown, wearing a distinctive backpack. At 6:44 a.m., he shot Thompson at a side entrance to the hotel, fled on foot, then climbed aboard a bicycle and within four minutes had entered Central Park, according to police. Another security camera recorded the gunman leaving the park near the American Museum of Natural History at 6:56 a.m. still on the bicycle but without the backpack, police said. After getting in a taxi, he headed north to a bus terminal near the George Washington Bridge, arriving at around 7:30 a.m. From there, the trail of video evidence runs cold. Police have not located video of the suspect exiting the building, leading them to believe he likely took a bus out of town. Police said they are still investigating the path the suspect took to Pennsylvania. “This just happened this morning," Kenny said. "We’ll be working, backtracking his steps from New York to Altoona, Pennsylvania,” Kenny said. Associated Press reporters Jamie Stengle, Lea Skene, Matt O'Brien, Sean Murphy and Cedar Attanasio contributed to this report.

None

LAMAR, Mo. — Lamar and Bowling Green fought literally to the last minute before the Tigers nailed down the 27-26 win and their chance to win a tenth state football championship in the last 13 years. The Lamar Tigers (10-4) advanced to play 14-0 Fair Grove at 3 p.m. Friday, Dec. 6, at Faurot Field at the University of Missouri in Columbia. Lamar sophomore Terren Williams led the Tigers' running attack with 55 yards and two touchdowns on 16 carries while senior Carson Sturgell had 34 yards and a touchdown on four carries. The Bobcats outran the Tigers on the ground with 329 yards to Lamar’s 171. Through the air, Lamar quarterback Alex Wilkerson completed six of 10 passes for 79 yards, including a 31-yard touchdown to junior Trent Torbeck in the third quarter. Bowling Green quarterback Jace Eskew completed four passes for 50 yards including a 24-yard touchdown to freshman wideout Tyler Obenhaus in the third quarter. Eskew also had an 89-yard rushing touchdown and completed a two-point pass for the Bobcat’s only lead in the game, of 20-14 in the third quarter. Lamar dominated the scoring in the first half with two touchdowns coming off Bowling Green mistakes. Bowling Green fumbled on the first play of their first possession of the game after forcing Lamar to punt in its opening possession. Lamar got the ball on the Bobcats' 32 yard line and scored on a 30-yard run by the Tigers' Carson Sturgell just three minutes into the contest. Bowling Green responded with a touchdown on its first possession of the second quarter capping a 10-play 54-yard drive. They failed to convert the two-point try and trailed 7-6 with 5:08 left in the second quarter. Lamar stopped Bowling Greene’s next drive and the Bobcat punter kicked the ball into the back of his own player giving Lamar the ball at the Bobcats' 18-yard line. Two holding penalties on the Tigers set them to first down and 30 yards at the Bobcats 38. Facing second and 26 at the 34-yard line, Wilkerson lost the handle of the ball on the snap but recovered to run for more than 20 yards and set up a third and 2 from the Bobcats 13. A 10-yard pass to Terren Williams, then a three-yard run by Williams put the Tigers up 14-6 at halftime. The Bobcats rallied in the third quarter for a 24-yard passing touchdown but missed the two-point conversion to cut Lamar’s lead to 14-12 with 6:24 left in the quarter. Bowling Green forced Lamar to punt on its next possession and the punt pinned the Bobcats at their own 11-yard line. Eskew took the first snap and ran around the Tigers left end to score on an 89-yard scamper. The Bobcats converted their first and only two-point conversion of the night going up 20-24 on Lamar but that didn’t last long. After a good kickoff return by Lamar’s special teams setting the Tigers up at the Bobcats' 32-yard line, Wilkerson converted the second play of this drive to a 30-yard touchdown to Torbeck and the Tigers took the lead back at 21-20. Lamar stopped Bowling Green’s next drive with a turnover on downs at Lamar’s 49-yard line and went 51 yards in 11 plays to score on a two-yard run by Williams. Lamar tried to go for two and the two-score lead over the Bobcats with 6:13 left in the fourth quarter but the conversion failed. Bowling Green started its final drive of the night at its own 28 and drove 72 yards in 18 plays, convening two fourth downs along the way to pull to within 27-26 with 58 seconds left in the game. Bowling Green’s runner was held short of the end zone by Lamar’s defense and the game ended with a 27-26 Lamar win in the Class 2 state semifinals.Key details about the man accused of killing of UnitedHealthcare's CEO

Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/) THOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025 , to all stockholders of record as of the close of business on February 14, 2025 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-announces-2025-first-quarter-dividend-302328180.html SOURCE AmgenWestern Digital CEO David Goeckeler Elected Chair of Semiconductor Industry Association

Will Gustav Nyquist Score a Goal Against the Stars on December 12? Published 5:33 pm Thursday, December 12, 2024 By Data Skrive Should you wager on Gustav Nyquist to score a goal when the Nashville Predators and the Dallas Stars go head to head on Thursday at 8:00 PM ET? In the article below, we dig into the numbers and trends you need to consider before making any bets. Sign up for ESPN+ today to watch 1,000+ out-of-market NHL games, ESPN+ Hockey Night & more. Will Gustav Nyquist score a goal against the Stars? Odds to score a goal this game: +390 (Bet $10 to win $39.00 if he scores a goal) Place your bets on any NHL matchup at BetMGM. Sign up today using our link. Nyquist stats and insights Catch NHL action all season long on Fubo. Stars defensive stats Catch NHL action all season long on Max. Nyquist recent games Predators vs. Stars game info Bet on this or any NHL matchup at BetMGM. Not all offers available in all states, please visit BetMGM for the latest promotions for your area. Must be 21+ to gamble, please wager responsibly. If you or someone you know has a gambling problem, contact 1-800-GAMBLER .

Apple working to support Sony’s VR controllers on Vision ProOracle misses quarterly results estimates on stiff cloud competition